SynthesisMedicina oral, patologia oral y cirugia bucal2026
Biomarkers in oral squamous cell carcinoma: a systematic review.
Synthesis in Medicina oral, patologia oral y cirugia bucal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Differential expression of hsa-miR-21-5p and hsa-miR-26a-5p in oral squamous cell carcinoma: A Single Centre pilot study.Molecular biology reports · 2026Article
- Tumor Biomarkers in Head and Neck Squamous Cell Carcinoma: From Etiology and Pathogenesis to Treatment Response-A Scoping Review.Biomedicines · 2026Review
- Chaperonin in health and disease.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral squamous cell carcinoma (OSCC) is one of the most aggressive cancers in the oral cavity, often diagnosed at advanced stages, leading to significantly reduced survival rates. Traditional diagnostic methods, such as clinical examination and histopathology, have limitations in detecting early stages and assessing tumor variability. Molecular biomarkers, however, have shown great potential in overcoming these limitations by improving early diagnosis, prognosis, and personalized treatment. These biomarkers, when integrated with the TNM staging system, may provide more accurate and personalized clinical management. MATERIAL AND
methodsA systematic review was conducted by searching PubMed, Scopus, and Web of Science databases for studies on biomarkers in OSCC published between January 2018 and December 2024. The studies were selected based on strict inclusion and exclusion criteria, focusing on those that investigated biomarkers related to OSCC diagnosis, prognosis, and therapeutic implications.
resultsThis review includes 10 studies involving 1024 patients with OSCC. Key biomarkers such as Ki67, HSP60, Survivin, E-cadherin, and PD-L1 were significantly associated with tumor progression, lymph node metastasis, and poor prognosis. The combined use of these biomarkers with traditional histopathological methods could enhance diagnostic accuracy, allowing for better patient stratification and more targeted treatment approaches. Additionally, saliva-based biomarkers have emerged as a promising, non-invasive diagnostic tool with high sensitivity and specificity for early detection of OSCC.
conclusionsThe identification of specific biomarkers can significantly enrich the diagnostic, prognostic, and therapeutic management of OSCC, complementing the TNM staging system. These biomarkers are linked to critical clinical variables such as metastasis, survival, and response to treatment. Saliva-based biomarkers hold promise due to their non-invasive nature, but further validation through multicenter studies and standardization is required for their widespread clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.